CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder
Article in Frontiers in Pharmacology (March 2024)
The most recent citing publications are shown below. View all 42 publications that cite this research output on Dimensions.
Article in Frontiers in Pharmacology (March 2024)
Book chapter (March 2024)
Article in European Respiratory Review (January 2024)